ArticleThe Korean journal of internal medicine2026

Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma.

Changgon Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.